Focusing on Inflammation and Immune Modification to Treat PH

All credits to Prof. Paul Hassoun FPVRI, Paul Hassoun, Professor of Medicine, Director, Pulmonary Hypertension Program at Johns Hopkins University, Baltimore- MD | United States

Presented at the 1st Annual Drug Discovery and Development Symposium, July 14-15th 2014, Bethesda, USA

Additional key-words: inflammation,immune system,autoimmunity,endothelium,

About the author

Paul Hassoun

United States

Focusing on Inflammation and Immune Modification to Treat PH

About the author

Paul Hassoun

More from this author

Our research platform is the world.

About the author

Paul Hassoun

More from this author

Related Content

{{GlobalController.truncateTitle("Role of Mesenchymal Cell-Macrophage Interactions in the Development of Pulmonary Vascular Remodeling and Hypertension - Dr. Kurt R. Stenmark", 65)}}

{{GlobalController.truncateTitle("Clinical Evidence of Inflammation in PAH: A Case Study of Profibrotic Macrophages - Dr. Jane A. Leopold", 65)}}

{{GlobalController.truncateTitle("An atypical presentation of adult-onset Still’s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature", 65)}}

{{GlobalController.truncateTitle("Tuning Nrf2 stress response to enhance host defense in COPD", 65)}}

{{GlobalController.truncateTitle("Animal models of pulmonary hypertension are consistently characterized by adventitial/peri-vascular accumulation of leukocytes, and in particular mononuclear cells", 65)}}

Add to reading list

Share this content

Our research platform is the world.